Given the substantial impairment of GSH production upon blocking CBP/p300 contribution to NRF2-dependent transcription, we next investigated how this may alter the lipid landscape of NRF2-dependent NSCLC cells. The gene discussed is EP300; the disease is non-small cell lung carcinoma.